CCR2 antagonism improves insulin resistance, lipid metabolism, and diabetic nephropathy in type 2 diabetic mice

Young Sun Kang, Mi Hwa Lee, Hye Kyoung Song, Gang Jee Ko, Oh Sung Kwon, Tae Kyung Lim, Sung Hwan Kim, Sang Youb Han, Kum Hyun Han, Ji Eun Lee, Jee Young Han, Hyoung Kyu Kim, Dae-Ryong Cha

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Chemokine ligand 2 (CCL2) binds to its receptor C-C chemokine receptor 2 (CCR2), initiating tissue inflammation, and recent studies have suggested a beneficial effect of a blockade of this pathway in diabetic nephropathy. To investigate the mechanism of protection, we studied the effect of RS504393, a CCR2 antagonist, on insulin resistance and diabetic nephropathy in db/db mice. Administering this antagonist improved insulin resistance as confirmed by various biomarkers, including homeostasis model assessment index levels, plasma insulin levels, and lipid abnormalities. Mice treated with the antagonist had a significant decrease in epididymal fat mass as well as phenotypic changes of adipocytes into small differentiated forms with decreased CCL2 expression and lipid hydroperoxide levels. In addition, treatment with the CCR2 antagonist markedly decreased urinary albumin excretion, mesangial expansion, and suppressed profibrotic and proinflammatory cytokine synthesis. Furthermore, the CCR2 antagonist improved lipid metabolism, lipid hydroperoxide, cholesterol, and triglyceride contents of the kidney, and decreased urinary 8-isoprostane levels. Hence, our findings suggest that CCR2 antagonists can improve insulin resistance by modulation of the adipose tissue and restore renal function through both metabolic and anti-fibrotic effects in type 2 diabetic mice.

Original languageEnglish
Pages (from-to)883-894
Number of pages12
JournalKidney International
Volume78
Issue number9
DOIs
Publication statusPublished - 2010 Nov 1

Fingerprint

CC Chemokines
Chemokine Receptors
Diabetic Nephropathies
Lipid Metabolism
Insulin Resistance
8-epi-prostaglandin F2alpha
Lipid Peroxides
Kidney
Chemokines
Adipocytes
Adipose Tissue
Albumins
Triglycerides
Homeostasis
Biomarkers
Fats
Cholesterol
Insulin
Cytokines
Ligands

Keywords

  • HOMA-IR
  • LPO
  • MCP-1
  • renal lipid metabolism

ASJC Scopus subject areas

  • Nephrology

Cite this

CCR2 antagonism improves insulin resistance, lipid metabolism, and diabetic nephropathy in type 2 diabetic mice. / Kang, Young Sun; Lee, Mi Hwa; Song, Hye Kyoung; Ko, Gang Jee; Kwon, Oh Sung; Lim, Tae Kyung; Kim, Sung Hwan; Han, Sang Youb; Han, Kum Hyun; Lee, Ji Eun; Han, Jee Young; Kim, Hyoung Kyu; Cha, Dae-Ryong.

In: Kidney International, Vol. 78, No. 9, 01.11.2010, p. 883-894.

Research output: Contribution to journalArticle

Kang, YS, Lee, MH, Song, HK, Ko, GJ, Kwon, OS, Lim, TK, Kim, SH, Han, SY, Han, KH, Lee, JE, Han, JY, Kim, HK & Cha, D-R 2010, 'CCR2 antagonism improves insulin resistance, lipid metabolism, and diabetic nephropathy in type 2 diabetic mice', Kidney International, vol. 78, no. 9, pp. 883-894. https://doi.org/10.1038/ki.2010.263
Kang, Young Sun ; Lee, Mi Hwa ; Song, Hye Kyoung ; Ko, Gang Jee ; Kwon, Oh Sung ; Lim, Tae Kyung ; Kim, Sung Hwan ; Han, Sang Youb ; Han, Kum Hyun ; Lee, Ji Eun ; Han, Jee Young ; Kim, Hyoung Kyu ; Cha, Dae-Ryong. / CCR2 antagonism improves insulin resistance, lipid metabolism, and diabetic nephropathy in type 2 diabetic mice. In: Kidney International. 2010 ; Vol. 78, No. 9. pp. 883-894.
@article{d1f863fb9cca498b96222f521bd363cf,
title = "CCR2 antagonism improves insulin resistance, lipid metabolism, and diabetic nephropathy in type 2 diabetic mice",
abstract = "Chemokine ligand 2 (CCL2) binds to its receptor C-C chemokine receptor 2 (CCR2), initiating tissue inflammation, and recent studies have suggested a beneficial effect of a blockade of this pathway in diabetic nephropathy. To investigate the mechanism of protection, we studied the effect of RS504393, a CCR2 antagonist, on insulin resistance and diabetic nephropathy in db/db mice. Administering this antagonist improved insulin resistance as confirmed by various biomarkers, including homeostasis model assessment index levels, plasma insulin levels, and lipid abnormalities. Mice treated with the antagonist had a significant decrease in epididymal fat mass as well as phenotypic changes of adipocytes into small differentiated forms with decreased CCL2 expression and lipid hydroperoxide levels. In addition, treatment with the CCR2 antagonist markedly decreased urinary albumin excretion, mesangial expansion, and suppressed profibrotic and proinflammatory cytokine synthesis. Furthermore, the CCR2 antagonist improved lipid metabolism, lipid hydroperoxide, cholesterol, and triglyceride contents of the kidney, and decreased urinary 8-isoprostane levels. Hence, our findings suggest that CCR2 antagonists can improve insulin resistance by modulation of the adipose tissue and restore renal function through both metabolic and anti-fibrotic effects in type 2 diabetic mice.",
keywords = "HOMA-IR, LPO, MCP-1, renal lipid metabolism",
author = "Kang, {Young Sun} and Lee, {Mi Hwa} and Song, {Hye Kyoung} and Ko, {Gang Jee} and Kwon, {Oh Sung} and Lim, {Tae Kyung} and Kim, {Sung Hwan} and Han, {Sang Youb} and Han, {Kum Hyun} and Lee, {Ji Eun} and Han, {Jee Young} and Kim, {Hyoung Kyu} and Dae-Ryong Cha",
year = "2010",
month = "11",
day = "1",
doi = "10.1038/ki.2010.263",
language = "English",
volume = "78",
pages = "883--894",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - CCR2 antagonism improves insulin resistance, lipid metabolism, and diabetic nephropathy in type 2 diabetic mice

AU - Kang, Young Sun

AU - Lee, Mi Hwa

AU - Song, Hye Kyoung

AU - Ko, Gang Jee

AU - Kwon, Oh Sung

AU - Lim, Tae Kyung

AU - Kim, Sung Hwan

AU - Han, Sang Youb

AU - Han, Kum Hyun

AU - Lee, Ji Eun

AU - Han, Jee Young

AU - Kim, Hyoung Kyu

AU - Cha, Dae-Ryong

PY - 2010/11/1

Y1 - 2010/11/1

N2 - Chemokine ligand 2 (CCL2) binds to its receptor C-C chemokine receptor 2 (CCR2), initiating tissue inflammation, and recent studies have suggested a beneficial effect of a blockade of this pathway in diabetic nephropathy. To investigate the mechanism of protection, we studied the effect of RS504393, a CCR2 antagonist, on insulin resistance and diabetic nephropathy in db/db mice. Administering this antagonist improved insulin resistance as confirmed by various biomarkers, including homeostasis model assessment index levels, plasma insulin levels, and lipid abnormalities. Mice treated with the antagonist had a significant decrease in epididymal fat mass as well as phenotypic changes of adipocytes into small differentiated forms with decreased CCL2 expression and lipid hydroperoxide levels. In addition, treatment with the CCR2 antagonist markedly decreased urinary albumin excretion, mesangial expansion, and suppressed profibrotic and proinflammatory cytokine synthesis. Furthermore, the CCR2 antagonist improved lipid metabolism, lipid hydroperoxide, cholesterol, and triglyceride contents of the kidney, and decreased urinary 8-isoprostane levels. Hence, our findings suggest that CCR2 antagonists can improve insulin resistance by modulation of the adipose tissue and restore renal function through both metabolic and anti-fibrotic effects in type 2 diabetic mice.

AB - Chemokine ligand 2 (CCL2) binds to its receptor C-C chemokine receptor 2 (CCR2), initiating tissue inflammation, and recent studies have suggested a beneficial effect of a blockade of this pathway in diabetic nephropathy. To investigate the mechanism of protection, we studied the effect of RS504393, a CCR2 antagonist, on insulin resistance and diabetic nephropathy in db/db mice. Administering this antagonist improved insulin resistance as confirmed by various biomarkers, including homeostasis model assessment index levels, plasma insulin levels, and lipid abnormalities. Mice treated with the antagonist had a significant decrease in epididymal fat mass as well as phenotypic changes of adipocytes into small differentiated forms with decreased CCL2 expression and lipid hydroperoxide levels. In addition, treatment with the CCR2 antagonist markedly decreased urinary albumin excretion, mesangial expansion, and suppressed profibrotic and proinflammatory cytokine synthesis. Furthermore, the CCR2 antagonist improved lipid metabolism, lipid hydroperoxide, cholesterol, and triglyceride contents of the kidney, and decreased urinary 8-isoprostane levels. Hence, our findings suggest that CCR2 antagonists can improve insulin resistance by modulation of the adipose tissue and restore renal function through both metabolic and anti-fibrotic effects in type 2 diabetic mice.

KW - HOMA-IR

KW - LPO

KW - MCP-1

KW - renal lipid metabolism

UR - http://www.scopus.com/inward/record.url?scp=77958102050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958102050&partnerID=8YFLogxK

U2 - 10.1038/ki.2010.263

DO - 10.1038/ki.2010.263

M3 - Article

VL - 78

SP - 883

EP - 894

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 9

ER -